The best outcomes are achieved in patients with liver-only disease, prior R0 resection of the primary tumor, at least six months of disease stability on systemic therapy, favorable tumor biology (RAS/BRAF wild-type, absence of high-risk co-mutations, microsatellite stability), low CEA (<80 μg/L), and no extrahepatic spread or high-risk metabolic tumor burden (<70 cm2 on ^18F-FDG PET/CT). This evidence concerns the gene BRAF and neoplasm.